The role of biologic agents in the management of non-infectious uveitis

Bibliography

• Deschenes J, Murray PI, Rao NA, Nussenblatt RB. International Uveitis Study Group (IUSG): clinical classification of uveitis. Ocul Immunol Inflamm 2008;16:1-2
   PubMed Web of Science ®Google Scholar
• Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 2004;111:491-500; discussion 00
   PubMed Web of Science ®Google Scholar
• McCannel CA, Holland GN, Helm CJ, Causes of uveitis in the general practice of ophthalmology. UCLA Community-Based Uveitis Study Group. Am J Ophthalmol 1996;121:35-46
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB. The natural history of uveitis. Int Ophthalmol 1990;14:303-8
   PubMed Web of Science ®Google Scholar
• Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 1996;80:332-6
   PubMed Web of Science ®Google Scholar
• Dana MR, Merayo-Lloves J, Schaumberg DA, Foster CS. Prognosticators for visual outcome in sarcoid uveitis. Ophthalmology 1996;103:1846-53
   PubMed Web of Science ®Google Scholar
• Reed JB, Morse LS, Schwab IR. High-dose intravenous pulse methylprednisolone hemisuccinate in acute Behcet retinitis. Am J Ophthalmol 1998;125:409-11
   PubMed Web of Science ®Google Scholar
• Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med 1948;238:787-93
   PubMed Web of Science ®Google Scholar
• Wong VG, Hersh EM. Methotrexate in the therapy of cyclitis. Trans Am Acad Ophthalmol Otolaryngol 1965;69:279-93
   Google Scholar
• Gangaputra S, Newcomb CW, Liesegang TL, Methotrexate for ocular inflammatory diseases. Ophthalmology 2009;116:2188-98. e1
   PubMed Web of Science ®Google Scholar
• Hamuryudan V, Ozyazgan Y, Hizli N, Azathioprine in Behcet's syndrome: effects on long-term prognosis. Arthritis Rheum 1997;40:769-74
   PubMed Web of Science ®Google Scholar
• Greenwood AJ, Stanford MR, Graham EM. The role of azathioprine in the management of retinal vasculitis. Eye (Lond) 1998;12(Pt 5):783-8
   PubMedGoogle Scholar
• Iaccarino L, Arienti S, Rampudda M, Mycophenolate mofetil in lupus glomerulonephritis: effectiveness and tolerability. Ann NY Acad Sci 2007;1110:516-24
   PubMed Web of Science ®Google Scholar
• Siepmann K, Huber M, Stubiger N, Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis: a retrospective analysis of 106 patients. Graefes Arch Clin Exp Ophthalmol 2006;244:788-94
   PubMed Web of Science ®Google Scholar
• Doycheva D, Deuter C, Stuebiger N, Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol 2007;91:180-4
   PubMed Web of Science ®Google Scholar
• Daniel E, Thorne JE, Newcomb CW, Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol 2010;149:423-32. e1-2
   PubMed Web of Science ®Google Scholar
• Galor A, Jabs DA, Leder HA, Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology 2008;115:1826-32
   PubMed Web of Science ®Google Scholar
• Okada AA. Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm 2005;13:335-51
   PubMed Web of Science ®Google Scholar
• Stepkowski SM. Molecular targets for existing and novel immunosuppressive drugs. Expert Rev Mol Med 2000;2:1-23
   PubMedGoogle Scholar
• Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol 2005;5:472-84
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Palestine AG, Chan CC. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol 1983;96:275-82
   PubMed Web of Science ®Google Scholar
• Masuda K, Nakajima A, Urayama A, Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet 1989;1:1093-6
   PubMed Web of Science ®Google Scholar
• Becker MD, Wertheim MS, Smith JR, Rosenbaum JT. Long-term follow-up of patients with birdshot retinochoroidopathy treated with systemic immunosuppression. Ocul Immunol Inflamm 2005;13:289-93
   PubMed Web of Science ®Google Scholar
• Araujo AA, Wells AP, Dick AD, Forrester JV. Early treatment with cyclosporin in serpiginous choroidopathy maintains remission and good visual outcome. Br J Ophthalmol 2000;84:979-82
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Palestine AG, Chan CC. Cyclosporine therapy for uveitis: long-term followup. J Ocul Pharmacol 1985;1:369-82
   PubMedGoogle Scholar
• Nussenblatt RB, Palestine AG, Chan CC, Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol 1991;112:138-46
   PubMed Web of Science ®Google Scholar
• Liu J. FK506 and cyclosporin, molecular probes for studying intracellular signal transduction. Immunol Today 1993;14:290-5
   PubMedGoogle Scholar
• O'Grady JG, Burroughs A, Hardy P, Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet 2002;360:1119-25
   PubMed Web of Science ®Google Scholar
• Ligtenberg G, Hene RJ, Blankestijn PJ, Koomans HA. Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus. J Am Soc Nephrol 2001;12:368-73
   PubMed Web of Science ®Google Scholar
• Mochizuki M, Masuda K, Sakane T, A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol 1993;115:763-9
   PubMed Web of Science ®Google Scholar
• Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology 1999;106:723-8
   PubMed Web of Science ®Google Scholar
• Murphy CC, Greiner K, Plskova J, Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol 2005;123:634-41
   PubMed Web of Science ®Google Scholar
• Hogan AC, McAvoy CE, Dick AD, Lee RW. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology 2007;114:1000-6
   PubMed Web of Science ®Google Scholar
• Sears ML, Chader G. Pharmacology of the Eye. Springer-Verlag; Berlin; New York: 1983
   Google Scholar
• Roda Perez E. Nitrogen mustard therapy of uveitis of unknown etiology. Rev Clin Esp 1952;44:173-80
   PubMedGoogle Scholar
• Pujari SS, Kempen JH, Newcomb CW, Cyclophosphamide for ocular inflammatory diseases. Ophthalmology 2010;117:356-65
   PubMed Web of Science ®Google Scholar
• Mamo JG, Azzam SA. Treatment of Behcet's disease with chlorambucil. Arch Ophthalmol 1970;84:446-50
   PubMed Web of Science ®Google Scholar
• Elliott JH, Ballinger WH. Behcet's syndrome: treatment with chlorambucil. Trans Am Ophthalmol Soc 1984;82:264-81
   PubMedGoogle Scholar
• Abdalla MI, el DBN. Long-lasting remission of Behcet's disease after chlorambucil therapy. Br J Ophthalmol 1973;57:706-11
   PubMed Web of Science ®Google Scholar
• Akpek EK, Jabs DA, Tessler HH, Successful treatment of serpiginous choroiditis with alkylating agents. Ophthalmology 2002;109:1506-13
   PubMed Web of Science ®Google Scholar
• Goldstein DA, Fontanilla FA, Kaul S, Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation. Ophthalmology 2002;109:370-7
   PubMed Web of Science ®Google Scholar
• Guesry P, Lenoir G, Broyer M. Gonadal effects of chlorambucil given to prepubertal and pubertal boys for nephrotic syndrome. J Pediatr 1978;92:299-303
   PubMed Web of Science ®Google Scholar
• Steege JF, Caldwell DS. Renal agenesis after first trimester exposure to chlorambucil. South Med J 1980;73:1414-15
   PubMed Web of Science ®Google Scholar
• Kauppi MJ, Savolainen HA, Anttila VJ, Isomaki HA. Increased risk of leukaemia in patients with juvenile chronic arthritis treated with chlorambucil. Acta Paediatr 1996;85:248-50
   PubMed Web of Science ®Google Scholar
• Khraishi M. Comparative overview of safety of the biologics in rheumatoid arthritis. J Rheumatol Suppl 2009;82:25-32
   PubMedGoogle Scholar
• Gueudry J, Wechsler B, Terrada C, Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet disease. Am J Ophthalmol 2008;146:837-44. e1
   PubMed Web of Science ®Google Scholar
• Tappeiner C, Heinz C, Specker C, Heiligenhaus A. Rituximab as a treatment option for refractory endogenous anterior uveitis. Ophthalmic Res 2007;39:184-6
   PubMed Web of Science ®Google Scholar
• Sadreddini S, Noshad H, Molaeefard M, Noshad R. Treatment of retinal vasculitis in Behcet's disease with rituximab. Mod Rheumatol 2008;18:306-8
   PubMed Web of Science ®Google Scholar
• Davatchi F, Shams H, Rezaipoor M, Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study). Int J Rheum Dis 2010;13:246-52
   PubMed Web of Science ®Google Scholar
• Isaacs JD, Hale G, Waldmann H, Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H. Br J Ophthalmol 1995;79:1054-5
   PubMed Web of Science ®Google Scholar
• Dick AD, Meyer P, James T, Campath-1H therapy in refractory ocular inflammatory disease. Br J Ophthalmol 2000;84:107-9
   PubMed Web of Science ®Google Scholar
• Lockwood CM, Hale G, Waldman H, Jayne DR. Remission induction in Behcet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology (Oxford) 2003;42:1539-44
   PubMed Web of Science ®Google Scholar
• Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol 2007;18:481-6
   PubMed Web of Science ®Google Scholar
• Suhler EB, Smith JR, Giles TR, Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol 2009;127:819-22
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Theodossiadis PG, Katsiari CG, Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 2001;358:295-6
   PubMed Web of Science ®Google Scholar
• Takamoto M, Kaburaki T, Numaga J, Long-term infliximab treatment for Behcet's disease. Jpn J Ophthalmol 2007;51:239-40
   PubMed Web of Science ®Google Scholar
• Al-Rayes H, Al-Swailem R, Al-Balawi M, Safety and efficacy of infliximab therapy in active behcet's uveitis: an open-label trial. Rheumatol Int 2008;29:53-7
   PubMed Web of Science ®Google Scholar
• Tanaka H, Sugita S, Yamada Y, Effects and safety of infliximab administration in refractory uveoretinitis with Behcet's disease. Nippon Ganka Gakkai Zasshi 2010;114:87-95
   PubMedGoogle Scholar
• Sfikakis PP, Kaklamanis PH, Elezoglou A, Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. Ann Intern Med 2004;140:404-6
   PubMed Web of Science ®Google Scholar
• Adan A, Hernandez V, Ortiz S, Effects of infliximab in the treatment of refractory posterior uveitis of Behcet's disease after withdrawal of infusions. Int Ophthalmol 2010;30:577-81
   PubMedGoogle Scholar
• Yamada Y, Sugita S, Tanaka H, Timing of recurrent uveitis in patients with Behcet's disease receiving infliximab treatment. Br J Ophthalmol 2011;95(2):205-8
   PubMed Web of Science ®Google Scholar
• Yamada Y, Sugita S, Tanaka H, Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behcet disease. Br J Ophthalmol 2010;94:284-8
   PubMed Web of Science ®Google Scholar
• El-Shabrawi Y, Hermann J. Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology 2002;109:2342-6
   PubMed Web of Science ®Google Scholar
• Sharma SM, Ramanan AV, Riley P, Dick AD. Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease. Ann Rheum Dis 2007;66:840-1
   PubMed Web of Science ®Google Scholar
• Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 2005;127:1064-71
   PubMed Web of Science ®Google Scholar
• Markomichelakis NN, Theodossiadis PG, Pantelia E, Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol 2004;138:648-50
   PubMed Web of Science ®Google Scholar
• Giansanti F, Barbera ML, Virgili G, Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behcet disease. Eur J Ophthalmol 2004;14:445-8
   PubMed Web of Science ®Google Scholar
• Adan A, Sanmarti R, Bures A, Casaroli-Marano RP. Successful treatment with infliximab in a patient with diffuse subretinal fibrosis syndrome. Am J Ophthalmol 2007;143:533-4
   PubMed Web of Science ®Google Scholar
• Jolly M, Curran JJ. Infliximab-responsive uveitis and vasculitis in a patient with Takayasu arteritis. J Clin Rheumatol 2005;11:213-15
   PubMed Web of Science ®Google Scholar
• Ally MR, Veerappan GR, Koff JM. Treatment of recurrent Crohn's uveitis with infliximab. Am J Gastroenterol 2008;103:2150-1
   PubMed Web of Science ®Google Scholar
• Niccoli L, Nannini C, Cassara E, Efficacy of infliximab therapy in two patients with refractory Vogt-Koyanagi-Harada disease. Br J Ophthalmol 2009;93:1553-4
   PubMed Web of Science ®Google Scholar
• Ardoin SP, Kredich D, Rabinovich E, Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am J Ophthalmol 2007;144:844-9
   PubMed Web of Science ®Google Scholar
• Reiff A, Takei S, Sadeghi S, Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001;44:1411-15
   PubMed Web of Science ®Google Scholar
• Smith JA, Thompson DJS, Whitcup SM, A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005;53:18-23
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE, Bradley DA, Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005;128:1062-47
   PubMed Web of Science ®Google Scholar
• Foster CS, Tufail F, Waheed NK, Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003;121:437-40
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005;52:2447-51
   PubMed Web of Science ®Google Scholar
• Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006;113:2317-23
   PubMed Web of Science ®Google Scholar
• Tynjala P, Lindahl P, Honkanen V, Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007;66:548-50
   PubMed Web of Science ®Google Scholar
• Diaz-Llopis M, Garcia-Delpech S, Salom D, Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 2008;24:351-61
   PubMed Web of Science ®Google Scholar
• Callejas-Rubio J, Sanchez-Cano D, Serrano J, Ortego-Centeno N. Comment on adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 2008;24:613-14
   PubMed Web of Science ®Google Scholar
• Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sight-threatening uveitis in Behcet's disease. Eye (Lond) 2007;21:824-5
   PubMed Web of Science ®Google Scholar
• Takase K, Ohno S, Ideguchi H, Successful switching to adalimumab in an infliximab-allergic patient with severe Behcet disease-related uveitis. Rheumatol Int 2011;31(2):243-5
   PubMed Web of Science ®Google Scholar
• Biester S, Deuter C, Michels H, Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007;91:319-24
   PubMed Web of Science ®Google Scholar
• Tynjala P, Kotaniemi K, Lindahl P, Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford) 2008;47:339-44
   PubMed Web of Science ®Google Scholar
• Simonini G, Taddio A, Cattalini M, Prevention of flare recurrences in childhood refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken) 2011;63(4):612-8
   PubMed Web of Science ®Google Scholar
• Diaz Llopis M, Amselem L, Romero FJ, Adalimumab therapy for Vogt-Koyanagi-Harada syndrome. Arch Soc Esp Oftalmol 2007;82:131-2
   PubMedGoogle Scholar
• Huynh N, Cervantes-Castaneda RA, Bhat P, Biologic response modifier therapy for psoriatic ocular inflammatory disease. Ocul Immunol Inflamm 2008;16:89-93
   PubMed Web of Science ®Google Scholar
• Guignard S, Gossec L, Salliot C, Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 2006;65:1631-4
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Rodevand E, Holck P, Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2009;68:696-701
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Fortin E, Schiffman R, Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci USA 1999;96:7462-6
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Thompson DJS, Li Z, Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun 2003;21:283-93
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Peterson JS, Foster CS, Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology 2005;112:764-70
   PubMed Web of Science ®Google Scholar
• Bhat P, Castaneda-Cervantes RA, Doctor PP, Foster CS. Intravenous daclizumab for recalcitrant ocular inflammatory disease. Graefes Arch Clin Exp Ophthalmol 2009;247:687-92
   PubMed Web of Science ®Google Scholar
• Yeh S, Wroblewski K, Buggage R, High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. J Autoimmun 2008;31:91-7
   PubMed Web of Science ®Google Scholar
• Sen HN, Levy-Clarke G, Faia LJ, High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis. Am J Ophthalmol 2009;148:696-703. e1
   PubMed Web of Science ®Google Scholar
• Gallagher M, Quinones K, Cervantes-Castaneda RA, Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol 2007;91:1341-4
   PubMed Web of Science ®Google Scholar
• Buggage RR, Levy-Clarke G, Sen HN, A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behcet's disease. Ocul Immunol Inflamm 2007;15:63-70
   PubMed Web of Science ®Google Scholar
• Martin R. Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis. Clin Immunol 2012;142:9-14
   PubMed Web of Science ®Google Scholar
• Hamuryudan V, Ozyazgan Y, Fresko Y, Interferon alfa combined with azathioprine for the uveitis of Behcet's disease: an open study. Isr Med Assoc J 2002;4:928-30
   PubMed Web of Science ®Google Scholar
• Sobaci G, Erdem U, Durukan AH, Safety and effectiveness of interferon alpha-2a in treatment of patients with Behcet's uveitis refractory to conventional treatments. Ophthalmology 2010;117:1430-5
   PubMed Web of Science ®Google Scholar
• Deuter CME, Zierhut M, Mohle A, Long-term remission after cessation of interferon-Œ ± treatment in patients with severe uveitis due to Behcet's disease. Arthritis Rheum 2010;62:2796-805
   PubMed Web of Science ®Google Scholar
• Gueudry J, Wechsler B, Terrada C, Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet disease. Am J Ophthalmol 2008;146:837-44
   PubMed Web of Science ®Google Scholar
• Sobaci G, Erdem U, Durukan AH, Safety and effectiveness of interferon alpha-2a in treatment of patients with Behcet's uveitis refractory to conventional treatments. Ophthalmology 2010;117:1430-5
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Orfanos CE. Treatment of Adamantiades-Behcet disease with systemic interferon alfa. Arch Dermatol 1998;134:1010-16
   PubMed Web of Science ®Google Scholar
• Kotter I, Gunaydin I, Zierhut M, Stubiger N. The use of interferon alpha in Behcet disease: review of the literature. Semin Arthritis Rheum 2004;33:320-35
   PubMed Web of Science ®Google Scholar
• Bodaghi B, Gendron G, Wechsler B, Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 2007;91:335-9
   PubMed Web of Science ®Google Scholar
• Paire V, Lebreton O, Weber M. Effectiveness of interferon alpha in the treatment of uveitis macular edema refractory to corticosteroid and/or immunosuppressive treatment. J Fr Ophtalmol 2010;33:152-62
   PubMed Web of Science ®Google Scholar
• Sobaci G, Bayraktar Z, Bayer A. Interferon alpha-2a treatment for serpiginous choroiditis. Ocul Immunol Inflamm 2005;13:59-66
   PubMed Web of Science ®Google Scholar
• Brasnu E, Wechsler B, Bron A, Efficacy of interferon-alpha for the treatment of Kaposi's sarcoma herpesvirus-associated uveitis. Am J Ophthalmol 2005;140:746-8
   PubMed Web of Science ®Google Scholar
• Touitou V, Sene D, Fardeau C, Interferon-alpha2a and Vogt-Koyanagi-Harada disease: a double-edged sword? Int Ophthalmol 2007;27:211-15
   PubMedGoogle Scholar
• Shahrara S, Huang Q, Mandelin AM II, Pope RM. TH-17 cells in rheumatoid arthritis. Arthritis Res Ther 2008;10:R93
   PubMed Web of Science ®Google Scholar
• Luger D, Silver PB, Tang J, Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med 2008;205:799-810
   PubMed Web of Science ®Google Scholar
• Chi W, Zhu XF, Yang PZ, Upregulated IL-23 and IL-17 in Behcet patients with active uveitis. Invest Ophthalmol Vis Sci 2008;49:3058-64
   PubMed Web of Science ®Google Scholar
• Hueber W, Patel DD, Dryja T, Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010;2(52):52ra72
   PubMed Web of Science ®Google Scholar
• Suhler EB, Smith JR, Wertheim MS, A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005;123:903-12
   PubMed Web of Science ®Google Scholar
• Molto A, Olive A. Anti-IL-1 molecules: new comers and new indications. Joint Bone Spine 2010;77:102-7
   PubMed Web of Science ®Google Scholar
• Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in muckle-wells syndrome and response to anakinra. Arthritis Rheum 2004;50:607-12
   PubMed Web of Science ®Google Scholar
• Church LD, McDermott MF. Rilonacept in cryopyrin-associated periodic syndromes: the beginning of longer-acting interleukin-1 antagonism. Nat Clin Pract Rheumatol 2009;5:14-15
   PubMedGoogle Scholar
• Zulian F, Balzarin M, Falcini F, Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken) 2010;62(6):821-5
   PubMed Web of Science ®Google Scholar
• Creed TJ, Norman MR, Probert CSJ, Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 2003;18:65-75
   PubMed Web of Science ®Google Scholar
• Feist E, Burmester GR. Canakinumab for treatment of cryopyrin-associated periodic syndrome. Expert Opin Biol Ther 2010;10:1631-6
   PubMed Web of Science ®Google Scholar
• McCann FE, Palfreeman AC, Andrews M, Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. Arthritis Res Ther 2010;12(3):R107
   PubMed Web of Science ®Google Scholar
• Ottiger M, Thiel MA, Feige U, Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer. Invest Ophthalmol Vis Sci 2009;50:779-86
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2006;2:619-26
   PubMedGoogle Scholar
• Brimhall AK, King LN, Licciardone JC, Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol 2008;159:274-85
   PubMed Web of Science ®Google Scholar
• Lee FF, Foster CS. Pharmacotherapy of uveitis. Expert Opin Pharmacother 2010;11:1135-46
   PubMed Web of Science ®Google Scholar
• Rituxan [package insert]. In: Biogen Idec, Inc. and Genentech USA I; South San Francisco: 2010
   Google Scholar
• Klastersky J. Adverse effects of the humanized antibodies used as cancer therapeutics. Curr Opin Oncol 2006;18:3116-20
   Web of Science ®Google Scholar
• Frampton JE, Wagstaff A. Alemtuzumab. Drugs 2003;63:1229-43
   PubMed Web of Science ®Google Scholar
• Gomez-Reino JJ, Carmona L, Valverde VR, Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-7
   PubMed Web of Science ®Google Scholar
• Askling J, Dixon W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008;20:138-44
   PubMed Web of Science ®Google Scholar
• Kempen JH, Daniel E, Dunn JP, Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ 2009;339:b2480
   PubMedGoogle Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85
   PubMed Web of Science ®Google Scholar
• Moreland LW, Weinblatt ME, Keystone EC, Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol 2006;33:854-61
   PubMed Web of Science ®Google Scholar
• Tyring S, Gordon KB, Poulin Y, Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007;143:719-26
   PubMed Web of Science ®Google Scholar
• Burmester GR, Mease P, Dijkmans BAC, Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009;68:1863-9
   PubMed Web of Science ®Google Scholar
• Ohno S, Nakamura S, Hori S, Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 2004;31:1362-8
   PubMed Web of Science ®Google Scholar
• Chung ES, Packer M, Lo KH, Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133-40
   PubMed Web of Science ®Google Scholar
• Taban M, Dupps WJ, Mandell B, Perez VL. Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature. Ocul Immunol Inflamm 2006;14:145-50
   PubMed Web of Science ®Google Scholar
• Kobashigawa J, David K, Morris J, Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids. Transplant Proc 2005;37:1333-9
   PubMed Web of Science ®Google Scholar
• Vincenti F, Kirkman R, Light S, Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998;338:161-5
   PubMed Web of Science ®Google Scholar
• Hershberger RE, Starling RC, Eisen HJ, Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 2005;352:2705-13
   PubMed Web of Science ®Google Scholar
• Newell FW, Krill AE. Treatment of uveitis with azathioprine (Imuran). Trans Ophthalmol Soc UK 1967;87:499-511
   PubMedGoogle Scholar
• Accorinti M, Pirraglia MP, Paroli MP, Infliximab treatment for ocular and extraocular manifestations of Behcet's disease. Jpn J Ophthalmol 2007;51:191-6
   PubMed Web of Science ®Google Scholar
• Yamada Y, Sugita S, Tanaka H, Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behcet disease. Br J Ophthalmol 2010;94:284-8
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Palestine AG, Rook AH, Treatment of intraocular inflammatory disease with cyclosporin A. Lancet 1983;2:235-8
   PubMed Web of Science ®Google Scholar
• Murphy CC, Ayliffe WH, Booth A, Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 2004;111:352-6
   PubMed Web of Science ®Google Scholar
• Kempen JH, Daniel E, Dunn JP, Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ 2009;339:b2480
   PubMedGoogle Scholar